Current Report Filing (8-k)
July 30 2020 - 8:34AM
Edgar (US Regulatory)
AMGEN INC false 0000318154 0000318154 2020-07-30 2020-07-30 0000318154 us-gaap:CommonStockMember 2020-07-30 2020-07-30 0000318154 amgn:A1.250SeniorNotesDue2022Member 2020-07-30 2020-07-30 0000318154 amgn:A2.00SeniorNotesDue2026Member 2020-07-30 2020-07-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2020
Amgen Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-37702
|
|
95-3540776
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
One Amgen Center Drive
Thousand Oaks
California
|
|
91320-1799
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(805) 447-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common stock, $0.0001 par value
|
|
AMGN
|
|
The Nasdaq Global Select Market LLC
|
|
1.250% Senior Notes Due 2022
|
|
AMGN22
|
|
New York Stock Exchange
|
|
2.000% Senior Notes Due 2026
|
|
AMGN26
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On July 30, 2020, Amgen Inc. (the “Company”) issued a press release announcing that it has commenced private offers to exchange certain outstanding debt securities of the Company for new debt securities of the Company.
A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Document Description
|
|
|
|
|
99.1
|
|
Press Release dated July 30, 2020.
|
|
|
|
|
104
|
|
Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
AMGEN INC.
|
|
|
|
|
|
|
Date: July 30, 2020
|
|
|
|
By:
|
|
/s/ Justin G. Claeys
|
|
|
|
|
|
Name:
|
|
Justin G. Claeys
|
|
|
|
|
|
Title:
|
|
Vice President, Finance and Treasurer
|
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
